ReviewMolecular neurobiology2026
Phosphorylated Tau Biomarkers in Alzheimer's Disease: From Early Detection to Clinical Potential-A Comprehensive Review.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genetic Determinants of Tau-PET Imaging in Alzheimer's Disease: A Narrative Review of Genome-Wide and Candidate-Gene Studies.Journal of imaging · 2026Review
- Standardized Extract of Ginkgo biloba L. Reverses Memory Impairment in Older Female Mice with Basal Forebrain Cholinergic Dysfunction.Neurochemical research · 2026Article
- Toward a Molecular Framework of Systemic Multi-Organ Toxicity Induced by Chronic Aluminum Chloride Exposure.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is characterized by the pathological accumulation of neurofibrillary tangles (NFTs) and amyloid plaques, with hyperphosphorylated tau protein playing a central role in the formation of NFTs. Among the various phosphorylation sites on tau, p-tau181, p-tau231, and p-tau217 have emerged as promising biomarkers for AD. In addition, given the complexity of tau modifications across multiple sites, recent studies have explored tau forms phosphorylated at several sites simultaneously, hypothesizing that multi-site phosphorylation may offer greater diagnostic value than single-site modifications. These biomarkers can be measured in plasma and cerebrospinal fluid (CSF) using immunoassays, and their levels can be correlated with neuroimaging techniques like positron emission tomography (PET) and magnetic resonance imaging (MRI). This review article comprehensively compares these three phosphorylation sites to evaluate their roles as biomarkers in AD, focusing on their diagnostic accuracy, utility in early detection, and potential for monitoring disease progression. Each biomarker offers unique advantages and disadvantages, which influence its applicability in both clinical and research settings. Further, the review also highlights the evolving nature of this field, emphasizing the need for standardized approaches and further research to validate these biomarkers across diverse populations and integrate them into routine clinical practice. By synthesizing current evidence, including recent validation of fully automated platforms for plasma p-tau, this article provides insights into the transformative potential of tau biomarkers for improving AD diagnosis and management. The FDA's clearance of a plasma p-tau217-based blood test in May 2025 represents a pivotal step toward accessible, non-invasive AD diagnostics. This development highlights the valuable role of tau as a potential biomarker for the disease.
Indexed as
Identifiers
41575615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.